vTv Therapeutics (VTVT) Net Cash Flow (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Net Cash Flow data on file, last reported at $9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 260.96% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at $67.0 million (up 416.22% YoY), and the FY2025 full-year result was $52.2 million, up 91.16% from the prior year.
• Net Cash Flow grew to $9.2 million in Q1 2026, from -$9.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $72.6 million in Q3 2025 to a low of -$9.6 million in Q4 2025.
• A 5-year average of $5.0 million and a median of -$3.2 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 499.42% in 2024 and jumped 1935.2% in 2025, its largest moves.
• Tracing VTVT's Net Cash Flow over 5 years: stood at -$3.2 million in 2022, then surged by 137.6% to $1.2 million in 2023, then tumbled by 499.42% to -$4.8 million in 2024, then plunged by 98.38% to -$9.6 million in 2025, then jumped by 195.63% to $9.2 million in 2026.
• Business Quant data shows VTVT's Net Cash Flow at $9.2 million in Q1 2026, -$9.6 million in Q4 2025, and $72.6 million in Q3 2025.